

























































A Sweet Galactose Transfer: Metabolic Oligosaccharide
Engineering as a Tool To Study Glycans in Plasmodium
Infection
Annabel Kitowski[a] and Gonçalo J. L. Bernardes*[a, b]
The introduction of chemical reporter groups into glycan
structures through metabolic oligosaccharide engineering
(MOE) followed by bio-orthogonal ligation is an important tool
to study glycosylation. We show the incorporation of synthetic
galactose derivatives that bear terminal alkene groups in
hepatic cells, with and without infection by Plasmodium berghei
parasites, the causative agent of malaria. Additionally, we
demonstrated the contribution of GLUT1 to the transport of
these galactose derivatives, and observed a consistent increase
in the uptake of these compounds going from naïve to P.
berghei-infected cells. Finally, we used MOE to study the
interplay between Plasmodium parasites and their mosquito
hosts, to reveal a possible transfer of galactose building blocks
from the latter to the former. This strategy has the potential to
provide new insights into Plasmodium glycobiology as well as
for the identification and characterization of key glycan
structures for further vaccine development.
Metabolic oligosaccharide engineering (MOE) is an important
tool in carbohydrate research and chemical biology.[1] Next to
proteins and nucleic acids, carbohydrates represent one of the
largest groups of biomolecules, with a wide range of function-
alities in health and disease states.[2] Although, for example,
changes in protein structures can be addressed through the
corresponding RNA sequence, carbohydrate structures are not
template-encoded, which can complicate their investigation.[3]
With the introduction of chemical reporter groups in glycan
structures through MOE, new strategies have been developed
to investigate glycan structures in different disease settings.
Over the years, different synthetic monosaccharide derivatives
of N-acetylmannosamine (ManNAc), N-acetylglucosamine
(GlcNAc), sialic acid and N-acetylglucosamine (GalNAc) have
been developed and used for MOE in different organisms and
experimental settings.[4] Typically MOE strategies use azides,
alkynes, terminal or strained alkenes, diazo groups or nitrones
as chemical reporter groups.[2c,4b] Recent work has focussed on
optimizing the required bioorthogonal labelling reactions in
terms of reaction kinetics and selectivity. Initially the focus was
on labelling reactions on the cell-surface, but more recent
studies showed intracellular labelling and tissue-specific enrich-
ment experiments.[5]
We decided to focus on the use of galactose, due to its
apparent importance in the context of infection by Plasmodium
parasites, the causative agents of malaria.[6] The glycobiology of
Plasmodium parasites has been amply discussed and is the
subject of several studies aimed at the identification of new
drug targets or vaccine antigens.[7] Recent research suggests
that the trisaccharide α-Gal and corresponding anti-α-Gal
antibodies play an important role in the acquisition of immunity
against malaria.[8] However, external factors are involved in the
level of expression of these antibodies and it remains unclear
how α-Gal is formed on the parasite.[8] During the course of a
Plasmodium infection, sporozoites injected by an infected
mosquito, travel in the blood stream from the initial injection
site to the liver and invade hepatocytes. In fact, by means of a
remarkable intrahepatic replication process, up to 40000
merozoites are released from each infected hepatocyte, which
initiates the symptomatic blood stage of infection.[9] This
important feature of the liver stage of Plasmodium infection
makes it a major target for the development of therapies and
vaccines. It has been shown that Plasmodium sporozoite
proteins, like the circumsporozoite protein (CSP), are presented
by infected hepatocytes during the liver stage and contribute,
together with so far unidentified antigen structures, to the
activation of CD8+ T cells.[10] This observation, together with
recent findings on the immunogenic properties of the α-Gal
epitope, suggested the potential presence of galactose contain-
ing glycan structures on infected cells. To test this hypothesis,
we decided to use synthetic galactose derivatives in combina-
tion with MOE to investigate different stages of Plasmodium
infection.[8a]
Baskin and co-workers have just disclosed 6-alkynyl uridine
diphosphate galactose derivatives, followed by click chemistry
tagging, to visualize glycosylation during zebrafish develop-
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ment. Together with the work presented here, it constitutes the
first examples of the use of galactose reporters with MOE to
study the roles of galactose in different biological settings.[11]
Starting from commercially available 1,6-anhydro-3,4-isopro-
pylidene-β-d-galactopyranose, three galactose derivatives with
differently sized terminal-alkene reporter groups were synthe-
sized (Figure 1a). The introduced chemical reporters were
addressed after metabolic incorporation through inverse elec-
tron-demand Diels-Alder (iEDDA) reaction with 6-methyl-tetra-
zine compounds. Briefly, derivatives 2a, 2b and 5 were
obtained through classical Williamson-ether synthesis, followed
by deprotection and acetylation of the monosaccharide.
Zémplen deacetylation resulted in deprotected derivatives 3a,
3b and 6 (see the Supporting Information). The determination
of the second-order rate constants for these derivatives in the
iEDDA reaction was conducted in 96-well-plates with a micro-
plate reader, and the decrease in specific tetrazine absorbance
at 530 nm was monitored. The measurements were performed
at 37 °C in PBS, pH 7.4. After determining the pseudo-first-order
rate constant kobs at different concentrations, an exponential
decay function was used to calculate the corresponding
second-order rate constants (Figure S1 in the Supporting
Information). In agreement with previous studies that used
mannosamine derivatives, the longer pentenyl-substituted
derivatives showed faster kinetics when reacted with 6-methyl-
tetrazine-amine relative to the shorter allyl-substituted deriva-
tive (Figure 1b).[12]
We started by employing these galactose derivatives to
study the liver stage of a Plasmodium infection. We considered
the importance of the α-Gal epitope for anti-malarial immunity
and sought to understand whether a change in galactose-
containing glycans was observed on hepatocytes after infection
with the Plasmodium parasite.[8b] We started by investigating
the metabolic incorporation of the synthesized galactose
derivatives into human hepatoma cells. In general, cells were
grown for 48–72 h in the presence of 100 μM of 2a, 2b, 5 or
natural counterpart penta-O-acetyl-d-galactose 9, before treat-
ment with 6-methyl-tetrazine-PEG4-biotin, which served as a
handle for further labelling (Figure 2a). All derivatives were
nontoxic at the concentrations employed in the experiments
(Figure S2). Huh7 and HepG2 cells were grown for 72 h in
complete Dulbecco’s modified Eagle’s medium, supplemented
with 100 μM of the galactose derivatives 2a, 2b, 5 and control
9, followed by labelling of the cell membrane with 6-methyl-
tetrazine-PEG4-biotin, which served as an handle for further
labelling, and Alexa-Fluor-568-streptavidin (Figure 2a). Analysis
and quantification of the fluorescence intensity was performed
by using confocal point-scanning microscopy and ImageJ
software. In compliance with the kinetic evaluations, a stronger
fluorescence signal was detected for derivatives 2b and 5
relative to 2a (Figures 2b and S3). The marginal signal increase
observed for derivative 5 relative to 2b may be explained by
the slightly higher kinetics of 5, due to its lower steric
hindrance, as a result of the presence of the pentenyl group in
Figure 1. a) Synthesis of galactose derivatives 2a, 2b, 3a, 3b, 5 and 6 for
metabolic labelling. b) Kinetic measurements and determination of the
second-order rate constant for the iEDDA reaction between tetrazine 7 and
monosaccharides 3a, 3b and 6.
Figure 2. a) Schematic description of the incorporation of galactose deriva-
tives into cell-surface glycans and targeting strategies with 6-methyl-
tetrazine-PEG4-biotin. b) Incorporation of 2a, 2b, and 5 in Huh7 cells,
labelling with Alexa-Fluor-568-streptavidin (red) and Hoechst (blue). c)
Incorporation of 2b, 5 and 9 into HepG2 cells and treatment with β-
galactosidase (1 U, 30 min, 37 °C), labelling with Alexa-Fluor-568-streptavidin
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C6 instead of C2. Compounds 5 and 2b represent unnatural
galactose derivatives, so we do not want to exclude different
interactions of these molecules with enzymes involved in glycan
biosynthesis. The switch of the terminal alkene reporter group
from C2 to C6 position can influence the recognition process by
necessary enzymes and therefore change the incorporation rate
into glycan structures. Epimerization to glucose was excluded
because no labelling was observed after treatment with β-
galactosidase (Figure 2c). The incorporation of 2b or 5 into
glycoprotein structures was also corroborated in pull-down
experiments (Figure S11). Additionally, inhibition experiments
with 9 and benzyl 2-acetamido-2-deoxy-d-galactopyranoside
confirmed the incorporation of 2b also in O-glycans in addition
to N-glycans (Figure S12 and S13).
Chen and co-workers reported cysteine S-glycosylation by
acetylated unnatural monosaccharides during MOE.[13] Thus, we
decided to attempt the direct incorporation of non-acetylated
derivative 3b in glycans present in the cell membrane of
HepG2 cells (Figure S5). Growing HepG2 cells for 72 h in the
presence of 3b (100 μM) resulted in the successful incorpo-
ration of the unprotected galactose derivative, which could be
fluorescently labelled by using our iEDDA approach. Our data
suggests the incorporation of the galactose derivatives into the
newly synthetized glycan structures rather than S-glycosylation.
Having shown successful incorporation of the artificial
galactose derivatives by human hepatic cells, we then sought
to investigate how this incorporation might change in the
context of the liver stage of Plasmodium infection. To this end,
HepG2 cells were infected with GFP-expressing P. berghei
sporozoites freshly isolated from salivary glands of infected
Anopheles mosquitoes, and the cells were grown in the
presence of 100 μM of 2b or 9 until 48 h post-infection (hpi).
Galactose incorporation was analysed by confocal point-scan-
ning microscopy and imaging flow cytometry (Figure 3a).
Confocal point-scanning microscopy showed a clear labelling of
the glycans in the cell membrane, both in uninfected and in P.
berghei-infected cells (Figure 3b). Incorporation of 2b was then
analysed by imaging flow cytometry 48 h after sporozoite
addition, which allows us to distinguish between infected cells,
which contain the GFP-expressing parasite, and uninfected cells
(Figure S6). To answer our question regarding the change of
galactose-containing glycans in P. berghei-infected hepatocytes,
we performed our MOE strategy using iEDDA reaction with 6-
methyl-tetrazine-PEG4-biotin and subsequent labelling with
Alexa-Fluor-568-streptavidin. Analysing this signal indicated a
slight yet consistent difference in uptake and incorporation of
2b by hepatocytes that were infected by P. berghei sporozoites
when compared to naïve hepatocytes (Figure 3c), although this
effect was not statistically significant. Furthermore, a consistent
difference in fluorescence was also detected between infected
cells and neighbouring uninfected cells.
The observation of a moderate increase of incorporated
galactose derivative 2b, could suggest a change in certain
metabolic events in P. berghei-infected hepatocytes. We started
to look into metabolic hallmarks, which are known to occur
during the course of parasite development in the infected
hepatic cell. Specifically, the importance of hexose transporters
for processes related to the energy metabolism of the
developing parasite caught our attention. It has been shown
that, during the blood stage of Plasmodium infection, glucose is
transported through GLUT1 into erythrocytes and taken up by
the parasite by a facilitative hexose transporter (PfHT).[14] GLUT1
is also expressed in liver cells and it has been shown that the
enhanced translocation of this transporter to the membrane of
P. berghei-infected hepatic cells, leads to increased glucose
uptake during the later stages of Plasmodium liver infection.[15]
GLUT1 belongs to a family of class I facilitative glucose
transporters, which also facilitates the diffusion of galactose.[16]
We hypothesized that the coherent increase observed in the
uptake of galactose derivative 2b by infected cells over naïve
ones, could be related with the reported increased translocation
of GLUT1 to the cell membrane of those cells. In this case, our
artificial galactose derivative 2b would also be transported
through the GLUT1 transporter.
To test this hypothesis, we selected two specific GLUT1
inhibitors, WZB117 10 and STF31 11, and nonspecific inhibitor
cytochalasin B 12 to block this transporter during the period of
incubation with galactose derivative 2b (Figure 4a). Briefly,
HepG2 cells were grown as before in the presence of 2b
(100 μM) for 72 h, in the presence of 10 μM of each inhibitor 10,
11 or 12. Interestingly, a decrease in fluorescence intensity was
Figure 3. a) Workflow for the infection of HepG2 cells with sporozoites from
P. berghei and metabolic incorporation of 2b. b) Metabolic labelling of
HepG2 cells with 2b or 9 after infection with GFP-sporozoites from P. berghei
(green), labelling with Alexa-Fluor-568-streptavidin (red) and Hoechst (blue)
48 hpi. Scale bars: 10 μm. c) Ratio of median fluorescence intensity from
Alexa-Fluor-568-streptavidin of naïve, uninfected and infected HepG2 cells,
acquired in Amnis ImageStreamX, ratio against corresponding control with
9. Data from four individual experiments were pooled, each data point
represents the median fluorescence intensity of 80 (infected) or 2000 cells
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observed in the presence of all the inhibitors employed, and a
dose-dependent decline in fluorescence intensity in the pres-
ence of the selective inhibitor 10 (Figures 4b, c and S8). These
results confirm the ability of GLUT1 to transport artificial
galactose structures into the cytosol. These results further
support the notion that P. berghei-infected hepatic cells have a
higher influx of derivative 2b, due to the increased trans-
location of GLUT1 transporters to the cell membrane of these
cells.
Having employed artificial galactose derivatives to inves-
tigate galactose uptake by Plasmodium-infected hepatic cells,
we then sought to extend our MOE approach to the study of
the Plasmodium parasite itself. As previously mentioned, the
presence of IgM antibodies against the trisaccharide α-Gal was
reported to provide a protective effect against malaria
transmission.[8a] Although the α-Gal epitope has been detected
on sporozoites from P. falciparum, P. berghei and P. yoelii, the
enzymes required for assembly of this epitope have not yet
been identified.[7a,8a] Residual levels of this epitope were also
detected in proteins from salivary glands of non-infected
Anopheles mosquitoes, which could suggest a transfer of
substrates or structures from the mosquito host to the
parasite.[8a] We therefore employed our MOE strategy to test
this hypothesis and assess a possible transfer of administered
galactose compounds from Anopheles mosquitoes to Plasmo-
dium parasites. To this end, female A. stephensi mosquitoes
were fed with a sugar solution, supplemented with either 2b or
its deprotected counterpart 3b. Pentaacetylated galactose 9 or
galactose 13 were used as negative controls in these experi-
ments. The feeding was initiated after the mosquitoes’ infec-
tious blood meal and was maintained for 21–24 days. After this
period, mosquito salivary glands were collected and P. berghei
sporozoites were isolated and analysed by imaging flow
cytometry (Figure 5a). Our results show that the fluorescence
intensity, which corresponds to the incorporated galactose
derivatives 2b or 3b, was significantly higher in sporozoites
dissected from mosquitoes fed on deprotected galactose
derivative 3b, than that observed in sporozoites obtained from
control mosquitoes. Thus, although the acetylated galactose
derivative 2b seemed not to be transferred from the mosquito
to the parasite, our labelling approach by means of iEDDA
reaction indicated the transfer of derivative 3b (Figure 5b). This
observed transfer of galactose molecules from the mosquito
host to the Plasmodium parasite could explain the reported
detections of α-Gal epitopes on the parasite surface. Interest-
ingly, the sporozoites obtained from mosquitoes fed on
derivative 3b, seem to be slightly bigger in size than
sporozoites obtained from the control mosquitoes, whereas a
smaller number of parasites was observed in the former than in
the latter (Figures S9 and S10). Further investigations into the
origin and biosynthetic pathways of the α-Gal epitope on
Plasmodium parasites would require many more factors to be
taken into account. Metabolic labelling experiments with the
isolated parasite or in different developmental stages can shed
light on this question, however, this should be addressed in a
separated work.
This proof-of-concept study demonstrates the application of
MOE with artificial galactose derivatives in the context of
Plasmodium infection. We showed the participation of GLUT1
transporters in the facilitated diffusion of the artificial galactose
derivatives and a reliable enhancement in the amount of
galactose derivative incorporated in P. berghei-infected hepatic
cells relative to that observed in naïve cells. The ability of
hexose transporters like GLUT1 to transport unnatural mono-
saccharide derivatives can be an important tool for further
studies in this area. Screening of different unnatural mono-
saccharide compounds could identify candidates, which are
significantly increased in P. berghei-infected cells and which
could be used as targeting agents, for example in drug-
conjugates. The application of per-acetylated monosaccharide
derivatives for MOE experiments is built on the assumption of
an endocytic or diffusion-based cell entry of these compounds.
Gilormini et al. demonstrated the participation of an as yet
Figure 4. a) GLUT1 inhibitors WZB117 10, STF31 11 and cytochalasine B 12.
b) Mean fluorescence intensity after metabolic incorporation of 2b in the
presence of 10 μM of inhibitors 10, 11 and 12; two-tailed Mann-Whitney. c)
Concentration-dependent decrease in fluorescence intensity after metabolic
incorporation of 2b with increasing concentration of inhibitor 10, pool of
two independent experiments; two-tailed Mann-Whitney.
Figure 5. a) Gating strategy for acquisition of Plasmodium berghei sporo-
zoites after incorporation of 3b. Scale bars: 1 μm. b) Comparison of
fluorescence intensity after labelling of sporozoites with 6-methyl-tetrazine-
sulfo-Cy3, after incorporation of galactose derivative 2b or control 9; two-
tailed Mann-Whitney. c) Comparison of fluorescence intensity after labelling
of sporozoites with 6-methyl-tetrazine-sulfo-Cy3, after incorporation of
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unknown transporter in the translocation of unnatural mannose
derivatives, which is supported by earlier studies by Varki and
co-workers.[17] In this context, our observation of a facilitated
diffusion of presented galactose derivative 2b through GLUT1
contributes to the notion of a more complex scenario then
simple diffusion, which should not be excluded as a parallel
transport route. In our study, the participation of GLUT1
provides a reasonable explanation for our observations. For
future applications of MOE, such transporters could provide a
tool for, for example enrichment of unnatural sugars in a
specific tissue or cell organelle.
We further employed the MOE approach to demonstrate
the transfer of the artificial galactose derivative 3b from the
mosquito host to the parasite. The impact of the introduction of
an artificial sugar structure on the quality and infectivity of the
sporozoites requires further investigation. Although we have
not addressed yet possible sugar transfers in other life-stages of
the parasite, these experiments could be used to gain further
understand of the glycobiology processes of the Plasmodium
parasite. In summary, the approach presented in this study
demonstrates the usefulness of MOE for further investigations
on the Plasmodium glycobiology and might open new
possibilities for the identification and characterization of
important glycan structures for vaccine development.
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